{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:35:31Z","timestamp":1792888531688,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00210-026-05642-w","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:45:44Z","timestamp":1783140344000},"page":"21685-21693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["1-Palmitoyl-4-piperidinopiperidine exhibits anticancer effects in murine triple-negative breast cancer EO771 cells associated with STAT3 signaling suppression"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-434X","authenticated-orcid":false,"given":"Hiroki","family":"Yoshioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Hamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayane","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanane","family":"Horita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rion","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azumi","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masumi","family":"Suzui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"5642_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3892\/ijo.2020.5160","volume":"58","author":"S Ando","year":"2021","unstructured":"Ando S, Fukamachi K, Yoshimoto E, Matsumoto H, Iinuma M, Suzui M (2021) Palmitoyl piperidinopiperidine, a novel derivative of 10-hydroxy-2-decenoic acid, as a potent and selective anticancer agent against human colon carcinoma cell lines. Int J Oncol 58:251\u2013265","journal-title":"Int J Oncol"},{"key":"5642_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46628-5","volume":"13","author":"J Arevalo","year":"2023","unstructured":"Arevalo J, Campoy I, Duran M, Nemours S, Areny A, Vall-Palomar M, Martinez C, Cantero-Recasens G, Meseguer A (2023) STAT3 phosphorylation at serine 727 activates specific genetic programs and promotes clear cell renal cell carcinoma (ccRCC) aggressiveness. Sci Rep 13:19552","journal-title":"Sci Rep"},{"key":"5642_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13045-021-01214-y","volume":"14","author":"N Awasthi","year":"2021","unstructured":"Awasthi N, Liongue C, Ward AC (2021) STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer. J Hematol Oncol 14:198","journal-title":"J Hematol Oncol"},{"key":"5642_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050755","author":"K Berkley","year":"2025","unstructured":"Berkley K, Zalejski J, Sharma A (2025) Targeting STAT3 for cancer therapy: focusing on Y705, S727, or dual inhibition? Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17050755","journal-title":"Cancers (Basel)"},{"key":"5642_CR5","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1038\/sj.onc.1203476","volume":"19","author":"J Bromberg","year":"2000","unstructured":"Bromberg J, Darnell JE Jr. (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19:2468\u20132473","journal-title":"Oncogene"},{"key":"5642_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-025-01359-0","volume":"15","author":"Z Chen","year":"2025","unstructured":"Chen Z, Liu Y, Lyu M, Chan CH, Sun M, Yang X, Qiao S, Chen Z, Yu S, Ren M, Lu A, Zhang G, Li F, Yu Y (2025) Classifications of triple-negative breast cancer: insights and current therapeutic approaches. Cell Biosci 15:13","journal-title":"Cell Biosci"},{"key":"5642_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/tkm2.70011","volume":"12","author":"J Hamanaka","year":"2025","unstructured":"Hamanaka J, Horiuchi A, Mikami Y, Yamashita S, Yamashita H, Horiguchi H, Suzui M, Yoshioka H (2025a) Antitumor effects of Sasa veitchii extract on human pancreatic adenocarcinoma cells. Tradit Kampo Med 12:143\u2013150","journal-title":"Tradit Kampo Med"},{"key":"5642_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/tkm2.1441","volume":"12","author":"J Hamanaka","year":"2025","unstructured":"Hamanaka J, Mikami Y, Horiuchi A, Yano A, Amano F, Shibata S, Ogata A, Ogata K, Nagatsu A, Miura N, Sano M, Suzui M, Yoshioka H (2025b) Sasa veitchii extract exhibits antitumor effect against murine pancreatic adenocarcinoma in vivo and in vitro. Tradit Kampo Med 12:10\u201319","journal-title":"Tradit Kampo Med"},{"key":"5642_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234191","volume":"15","author":"AS Hamy","year":"2020","unstructured":"Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT, Evrevin C, Rozette S, Laot L, Lerebours F, Pierga JY, Osdoit M, Faron M, Feron JG, Lae M, Reyal F (2020) Prognostic value of the residual cancer burden index according to breast cancer subtype: validation on a cohort of BC patients treated by neoadjuvant chemotherapy. PLoS ONE 15:e0234191","journal-title":"PLoS ONE"},{"key":"5642_CR10","first-page":"265","volume":"17","author":"H Jie","year":"2025","unstructured":"Jie H, Ma W, Huang C (2025) Diagnosis, prognosis, and treatment of triple-negative breast cancer: a review. Breast Cancer (Dove Med Press) 17:265\u2013274","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"5642_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-98176-9","volume":"15","author":"SY Lee","year":"2025","unstructured":"Lee SY, Yoo TK, Lee SB, Kim J, Chung IY, Ko BS, Kim HJ, Lee JW, Son BH (2025) Prognostic value of residual cancer burden after neoadjuvant chemotherapy in breast cancer: a comprehensive subtype-specific analysis. Sci Rep 15:13977","journal-title":"Sci Rep"},{"key":"5642_CR12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3892\/ijo.2017.3846","volume":"50","author":"B Li","year":"2017","unstructured":"Li B, Huang C (2017) Regulation of EMT by STAT3 in gastrointestinal cancer (review). Int J Oncol 50:753\u2013767","journal-title":"Int J Oncol"},{"key":"5642_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12935-025-03769-z","volume":"25","author":"H Li","year":"2025","unstructured":"Li H, Chang Y, Jin T, Zhang M (2025) Progress of PD-1\/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer. Cancer Cell Int 25:139","journal-title":"Cancer Cell Int"},{"key":"5642_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12964-020-0527-z","volume":"18","author":"JH Ma","year":"2020","unstructured":"Ma JH, Qin L, Li X (2020) Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal 18:33","journal-title":"Cell Commun Signal"},{"key":"5642_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.866014","volume":"12","author":"SG Manore","year":"2022","unstructured":"Manore SG, Doheny DL, Wong GL, Lo HW (2022) IL-6\/JAK\/STAT3 signaling in breast cancer metastasis: biology and treatment. Front Oncol 12:866014","journal-title":"Front Oncol"},{"key":"5642_CR16","doi-asserted-by":"publisher","first-page":"6565","DOI":"10.1158\/0008-5472.CAN-09-0913","volume":"69","author":"CP Masamha","year":"2009","unstructured":"Masamha CP, Benbrook DM (2009) Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res 69:6565\u20136572","journal-title":"Cancer Res"},{"key":"5642_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.semcancer.2020.03.016","volume":"80","author":"CD Mohan","year":"2022","unstructured":"Mohan CD, Rangappa S, Preetham HD, Chandra Nayaka S, Gupta VK, Basappa S, Sethi G, Rangappa KS (2022) Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature. Semin Cancer Biol 80:157\u2013182","journal-title":"Semin Cancer Biol"},{"key":"5642_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cancergen.2025.03.004","volume":"294\u2013295","author":"S Narote","year":"2025","unstructured":"Narote S, Desai SA, Patel VP, Deshmukh R, Raut N, Dapse S (2025) Identification of new immune target and signaling for cancer immunotherapy. Cancer Genet 294\u2013295:57\u201375","journal-title":"Cancer Genet"},{"key":"5642_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020448","author":"CM Pfeffer","year":"2018","unstructured":"Pfeffer CM, Singh ATK (2018) Apoptosis: a target for anticancer therapy. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19020448","journal-title":"Int J Mol Sci"},{"key":"5642_CR20","doi-asserted-by":"publisher","first-page":"9408","DOI":"10.1200\/JCO.2005.01.5594","volume":"23","author":"GK Schwartz","year":"2005","unstructured":"Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23:9408\u20139421","journal-title":"J Clin Oncol"},{"key":"5642_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102164","volume":"6","author":"ES Seo","year":"2025","unstructured":"Seo ES, Park S, Cho EY, Lee JE, Jung HH, Hyeon J, An S, Kim SW, Shin J, Ahn JS, Park YH, Im YH, Kim H, Lee S, Park WY, Kim JY (2025) Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype. Cell Rep Med 6:102164","journal-title":"Cell Rep Med"},{"key":"5642_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020429","author":"SQ To","year":"2022","unstructured":"To SQ, Dmello RS, Richards AK, Ernst M, Chand AL (2022) STAT3 signaling in breast cancer: multicellular actions and therapeutic potential. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14020429","journal-title":"Cancers (Basel)"},{"key":"5642_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2220\/biomedres.45.143","volume":"45","author":"S Tominaga","year":"2024","unstructured":"Tominaga S, Yoshioka H, Yokota S, Tsukiboshi Y, Suzui M, Nagai M, Hara H, Miura N, Maeda T (2024) Copper-induced renal toxicity controlled by period1 through modulation of Atox1 in mice. Biomed Res 45:143\u2013149","journal-title":"Biomed Res"},{"key":"5642_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2131\/jts.49.1","volume":"49","author":"Y Tsukiboshi","year":"2024","unstructured":"Tsukiboshi Y, Horita H, Mikami Y, Noguchi A, Yokota S, Ogata K, Yoshioka H (2024) Involvement of microRNA-4680-3p against phenytoin-induced cell proliferation inhibition in human palate cells. J Toxicol Sci 49:1\u20138","journal-title":"J Toxicol Sci"},{"key":"5642_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032969","author":"NS van den Ende","year":"2023","unstructured":"van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R, van Deurzen CHM (2023) Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24032969","journal-title":"Int J Mol Sci"},{"key":"5642_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamaoncol.2024.3456","volume":"10","author":"G Villacampa","year":"2024","unstructured":"Villacampa G, Navarro V, Matikas A, Ribeiro JM, Schettini F, Tolosa P, Martinez-Saez O, Sanchez-Bayona R, Ferrero-Cafiero JM, Salvador F, Papakonstantinou A, Prat A, Oliveira M, Pascual T (2024) Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: a systematic review and meta-analysis. JAMA Oncol 10:1331\u20131341","journal-title":"JAMA Oncol"},{"key":"5642_CR27","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796\u20131804","journal-title":"J Clin Oncol"},{"key":"5642_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13105-9","volume":"24","author":"Z Wang","year":"2024","unstructured":"Wang Z, You P, Yang Z, Xiao H, Tang X, Pan Y, Li X, Gao F (2024) PD-1\/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety. BMC Cancer 24:1339","journal-title":"BMC Cancer"},{"key":"5642_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.cancergen.2025.07.009","volume":"296\u2013297","author":"Q Wei","year":"2025","unstructured":"Wei Q, Yang Y, Wang H, Li C, Li Y (2025) The mechanism of lncRNA SSTR5-AS1 promoting ferroptosis resistance and immune escape in ovarian cancer cells by recruiting STAT3 to regulate SLC7A11 expression. Cancer Genet 296\u2013297:172\u2013181","journal-title":"Cancer Genet"},{"key":"5642_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030526","author":"T Yang","year":"2023","unstructured":"Yang T, Li W, Huang T, Zhou J (2023) Immunotherapy targeting PD-1\/PD-L1 in early-stage triple-negative breast cancer. J Pers Med. https:\/\/doi.org\/10.3390\/jpm13030526","journal-title":"J Pers Med"},{"key":"5642_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/tkm2.1417","volume":"11","author":"H Yoshioka","year":"2024","unstructured":"Yoshioka H, Tominaga S, Amano F, Wu S, Torimoto S, Moriishi T, Tsukiboshi Y, Yokota S, Miura N, Inagaki N, Matsushita Y, Maeda T (2024) Juzentaihoto alleviates cisplatin-induced renal injury in mice. Tradit Kampo Med 11:147\u2013155","journal-title":"Tradit Kampo Med"},{"key":"5642_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2220\/biomedres.46.1","volume":"46","author":"H Yoshioka","year":"2025","unstructured":"Yoshioka H, Horita H, Tsukiboshi Y, Kurita H, Mikami Y, Ogata K, Ogata A (2025) Mycophenolate mofetil reduces cell viability associated with the miR-205-PAX9 pathway in human lip fibroblast cells. Biomed Res 46:1\u20138","journal-title":"Biomed Res"},{"key":"5642_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cancergen.2026.02.002","volume":"302\u2013303","author":"H Yoshioka","year":"2026","unstructured":"Yoshioka H, Hamanaka J, Horiuchi A, Horita H, Horiguchi H, Suzui M (2026) Anticancer effect of palmitoyl piperidinopiperidine against human pancreatic ductal adenocarcinoma cells. Cancer Genet 302\u2013303:139\u2013143","journal-title":"Cancer Genet"},{"key":"5642_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153172","volume":"68","author":"ZH Zhang","year":"2020","unstructured":"Zhang ZH, Li MY, Wang Z, Zuo HX, Wang JY, Xing Y, Jin C, Xu G, Piao L, Piao H, Ma J, Jin X (2020) Convallatoxin promotes apoptosis and inhibits proliferation and angiogenesis through crosstalk between JAK2\/STAT3 (T705) and mTOR\/STAT3 (S727) signaling pathways in colorectal cancer. Phytomedicine 68:153172","journal-title":"Phytomedicine"},{"key":"5642_CR35","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.7150\/ijbs.103723","volume":"21","author":"L Zhang","year":"2025","unstructured":"Zhang L, Wang L, Xu Z, Zhang X, Guan S, Liu Z, Gu S, Zhao L, Bai W, Li T, Zhao X (2025) eNAMPT\/Ac-STAT3\/DIRAS2 axis promotes development and cancer stemness in triple-negative breast cancer by enhancing cytokine crosstalk between tumor-associated macrophages and cancer cells. Int J Biol Sci 21:2027\u20132047","journal-title":"Int J Biol Sci"},{"key":"5642_CR36","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41401-021-00718-0","volume":"43","author":"Y Zhong","year":"2022","unstructured":"Zhong Y, Deng L, Shi S, Huang QY, Ou-Yang SM, Mo JS, Zhu K, Qu XM, Liu PQ, Wang YX, Zhang XL (2022) The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts. Acta Pharmacol Sin 43:1013\u20131023","journal-title":"Acta Pharmacol Sin"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05642-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:01:28Z","timestamp":1792886488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05642-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":36,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5642"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05642-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The author noticed that some text in the supplementary information is still highlighted in yellow.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}